AD-2091
/ Yuhan Corp
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
May 21, 2024
Phase III Study to Evaluate the Efficacy and Safety of AD-209
(clinicaltrials.gov)
- P3 | N=280 | Recruiting | Sponsor: Addpharma Inc. | Not yet recruiting ➔ Recruiting
Enrollment open • Cardiovascular • Hypertension
1 to 1
Of
1
Go to page
1